Avadel Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced that CEO Greg Divis will join a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 1:40 p.m. ET. A live webcast and an archived recording will be available on the company’s Investor Relations website for 90 days post-conference.

Avadel focuses on transforming medicines, with its lead drug candidate, FT218, aimed at treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 1:40 p.m. ET.

A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following the conference.

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.

Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687

Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292

FAQ

When will Greg Divis participate in the SVB Leerink Global Healthcare Conference?

Greg Divis will participate in the conference on February 17, 2022, at 1:40 p.m. ET.

Where can I find the webcast of the AVDL conference chat?

The webcast will be available on Avadel's Investor Relations website for 90 days after the event.

What is the focus of Avadel Pharmaceuticals?

Avadel Pharmaceuticals focuses on transforming medicines, especially through innovative solutions in biopharmaceuticals.

What is the lead drug candidate of Avadel Pharmaceuticals?

The lead drug candidate is FT218, designed for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy.

What technology does FT218 utilize?

FT218 leverages a proprietary drug delivery technology for its formulation.